Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced that the company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell name:
• Cell-Ess Serum Replacement cell culture medium
• Cryo-Ess cryopreservation medium
• Clin-Ess transportation medium
“The quality and consistency of Cell-Ess, Cryo-Ess, and Clin-Ess gives scientists the confidence to conduct their research without testing each new serum lot purchased, resulting in improved laboratory efficiency and valuable cost savings,” said Allan Weber, chief executive officer of Essential Pharmaceuticals. “Moreover, we believe that the characteristics of these media products offer important clinical benefits, making Cell-Ess the ideal choice for use in the cutting edge areas of stem cell, cancer and vaccine research, and Clin-Ess in the preservation of limbs and organs for surgical applications.”
The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers the advantage of superior performance compared to fetal bovine serum. They are free of all animal components and dimethyl sulfoxide (DSMO), do not crystallize or form ice during the thawing process, resulting in less DNA and RNA degradation and fewer artifacts than those preserved using conventional methods. Further, they have demonstrated synthetic reproducibility with no lot-to-lot variability.
Essential Pharmaceuticals acquired exclusive worldwide rights to these media products, originally the LiforCell family of products, from Lifeblood Medical, Inc. These cell culture and cryopreservation products have been re-branded to correlate to their specific research and clinical applications.
“Essential Pharmaceuticals is known for its outstanding customer support in highly specialized fields,” stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical. “That, along with the superior advantages of these cell culture and cryopreservation media, will generate increased growth and market penetration of the Lifeblood technology.”
